Literature DB >> 15270736

Dual biological functions of an interleukin-1 receptor antagonist-interleukin-10 fusion protein and its suppressive effects on joint inflammation.

Deh-Ming Chang1, Song-Kun Shyue, Shao-Hsiang Liu, Yen-Teen Chen, Chiou-Yueh Yeh, Jenn-Huang Lai, Herng-Sheng Lee, Ann Chen.   

Abstract

The aim of this study was to construct and purify a novel interleukin-1 receptor antagonist (IL-1ra)-interleukin-10 (IL-10) fusion protein and determine its biological function and anti-inflammatory effects. The isolated cDNAs of two inhibitory cytokines (IL-1ra, IL-10) were used to construct a cDNA for the IL-1ra-IL-10 fusion protein. The expressed recombinant cytokines and fusion product were purified and their biological properties analysed. The anti-IL-1 effect was evaluated by using a thymocyte-proliferation assay, and the IL-10 effect was investigated by the inhibition of interferon-gamma (IFN-gamma) production from splenocytes. The clinical response and histological analyses were studied in an adjuvant arthritic rat model. The fusion protein was 38 000 molecular weight in size. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting demonstrated that the purified protein was recognized by both IL-1ra and IL-10 antibodies. The fusion protein significantly inhibited IL-1-mediated thymocyte proliferation and concanavalin A (ConA)-primed IFN-gamma production from splenocytes. The fusion protein also suppressed joint swelling (paw circumference reduced from 5.0 +/- 0.2 to 4.1 +/- 0.1 cm; paw thickness approximately 2 mm in difference) and synovial inflammation in adjuvant arthritis of rats. Our investigations indicate that this fusion protein effectively suppresses inflammatory arthritis and may initiate a trend for future clinical application to target multiple molecules at the same time.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15270736      PMCID: PMC1782518          DOI: 10.1111/j.1365-2567.2004.01910.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  40 in total

1.  Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer.

Authors:  K N Kim; S Watanabe; Y Ma; S Thornton; E H Giannini; R Hirsch
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

Review 2.  Pro- and anti-inflammatory cytokines in rheumatoid arthritis.

Authors:  P Isomäki; J Punnonen
Journal:  Ann Med       Date:  1997-12       Impact factor: 4.709

Review 3.  Interleukin-1 receptor antagonist: role in biology.

Authors:  W P Arend; M Malyak; C J Guthridge; C Gabay
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

4.  Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis.

Authors:  K Yudoh; H Matsuno; F Nakazawa; T Yonezawa; T Kimura
Journal:  Arthritis Rheum       Date:  2000-03

Review 5.  IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis.

Authors:  E Keystone; J Wherry; P Grint
Journal:  Rheum Dis Clin North Am       Date:  1998-08       Impact factor: 2.670

6.  IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells.

Authors:  T Aarvak; M Chabaud; P Miossec; J B Natvig
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

7.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

Authors:  B Bresnihan; J M Alvaro-Gracia; M Cobby; M Doherty; Z Domljan; P Emery; G Nuki; K Pavelka; R Rau; B Rozman; I Watt; B Williams; R Aitchison; D McCabe; P Musikic
Journal:  Arthritis Rheum       Date:  1998-12

8.  Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis. More therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone.

Authors:  E Lubberts; L A Joosten; M M Helsen; W B van den Berg
Journal:  Cytokine       Date:  1998-05       Impact factor: 3.861

9.  Direct synovial gene transfer with retroviral vectors in rat adjuvant arthritis.

Authors:  K H Nguyen; D L Boyle; J E McCormack; S Chada; D J Jolly; G S Firestein
Journal:  J Rheumatol       Date:  1998-06       Impact factor: 4.666

10.  Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis.

Authors:  G Horneff; U Sack; J R Kalden; F Emmrich; G R Burmester
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.